A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Inclusion Criteria:
Exclusion Criteria:
Union City, Georgia 30291, United States
Skokie, Illinois 60077, United States
Fayette, Mississippi 39069, United States
Greenville, South Carolina 29607, United States
CABA, Buenos Aires 1060, Argentina
CABA, Buenos Aires 1120, Argentina
CABA, Buenos Aires C1407GTN, Argentina
CABA, Buenos Aires C1425AGC, Argentina
CABA, Buenos Aires C1426ABP, Argentina
CABA, Buenos Aires C1426ABP, Argentina
Ciudad Autonoma de Buenos Aires, Buenos Aires C1056ABI, Argentina
Ciudad Autonoma de Buenos Aires, Buenos Aires C1061AAT, Argentina
Mons, 7000, Belgium
North York, Ontario M6B 3H7, Canada
Chiyoda-ku, Tokyo 101-0041, Japan
Chuo-ku, Tokyo 104-0031, Japan
Hachioji-shi, Tokyo 192-0046, Japan
Minato-ku, Tokyo 108-0075, Japan
Shinjuku-ku, Tokyo 160-0004, Japan
Suginami-ku, Tokyo 166-0003, Japan
Bialystok, 15-281, Poland
Katowice, 40-752, Poland
Ansan-si, Gyeonggi-do, 15355, South Korea
Anyang-si, Gyeonggi-do, 14068, South Korea
Bucheon, Gyeonggi-do, 14647, South Korea
Goyang-si, Gyeonggi-do, 10326, South Korea
Seongnam-si, Gyeonggi-do, 13620, South Korea
Seoul, 07061, South Korea
Suwon-si Gyeonggi-do, 16499, South Korea
Cornwall, PL11 2TB, United Kingdom
Leicester, LE5 4PW, United Kingdom